Letters

Long term safety of statins should be monitored

BMJ 2006; 333 doi: http://dx.doi.org/10.1136/bmj.333.7569.656 (Published 21 September 2006) Cite this as: BMJ 2006;333:656
  1. Steven J Haas, honorary research fellow ([email protected]),
  2. Rosana Hage-Ali, research assistant,
  3. Brian G Priestly, director, Australian Centre for Human Health Risk,
  4. Andrew Tonkin, head, cardiovascular unit,
  5. Lisa Demos, senior research fellow,
  6. John J McNeil, head,
  7. Mark Nelson, chair, discipline of general practice
  1. Monash University, Department of Epidemiology and Preventive Medicine, Central and Eastern Clinical School, Alfred Hospital, 89 Commercial Road, Melbourne, VIC 3004, Australia
  2. Monash University, Department of Epidemiology and Preventive Medicine, Central and Eastern Clinical School, Alfred Hospital, 89 Commercial Road, Melbourne, VIC 3004, Australia
  3. School of Medicine, University of Tasmania, Private Bag 33, Hobart, Tasmania 7001, Australia

    EDITOR—We agree with Ravnskov et al that little is known about the adverse effects of high dose statins but also propose that little is known about the long term safety of more modest doses used at present.1 Lifetime use of statins may equate to treatment for 30 years or more.2 As said by the authors, multicentre, large scale trials have established efficacy of these agents but are much …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe